Call for Speakers

September 2018 Practice Management Program

Investigational Drug Service:

This 90-minute session will feature three speakers (approximately 20 minutes per presentation) and a robust Q&A exchange with the audience. We are seeking three speakers, each one to address one of the following topics:

  • Describe use and implementation of computerized software for managing an investigational drug service (e.g. Vestigo, or other). The presentation should consider description of transition from paper to software; use of the software for billing, accounting and report generation to maximize efficiency if possible. The speaker should have experience using one of the software programs.
  • Vaccine and viral vector studies: describe facility challenges, budgetary constraints, barriers to implementation of biohazardous trials; how to set fees for these trials, if different from standard clinical trials. Incorporation of nursing perspectives can also be considered. The speaker should have experience managing and implementing vaccine and/or viral vector studies.
  • Establishing and negotiating IDS fees: Describe how to determine an appropriate fee for pharmacy IDS services and how they relate to the total fee charged by the institution for conducting a study. A discussion of typical university taxes on studies would also be appropriate. Describe tips for negotiating with pharmaceutical study partners.

Value Based Care

This 30-minute session will feature one speaker. The preferred speaker will have experience participating in the CMS Oncology Care Model pilot. The speaker will:

  • Showcase experience with the Oncology Care Model
  • Discuss implementation and challenges for pharmacists and the organization
  • Describe opportunities to incorporate or justify oncology pharmacist participation within the model

Information Technology (IT)

This 60-minute session will feature one speaker. The speaker should have experience withclinical informatics or spend a portion of his or her time on data analytics and report generation or assessment to support clinical functions. In particular, the speaker should address:

  • Explainreport development that will be able to provide information that can be used to support clinical or financial decisions
  • Identify meaningful outcomes measures that define value and/or quality (e.g. could include readmission rates, or other clinical outcomes measured over time)
  • Describe what data and data collection methods can be used to support certifications (e.g. QOPI, COC)

CAR-T Implementation

This 60-minute talk will feature one speaker. The speaker should be experienced with the implementation of the FDA-approved CAR product. The preferred speaker will address:

  • Financial considerationsfor pharmacies, health-systems and patients when implementing CAR therapy
  • Describe billing and reimbursement experience with CAR therapy
  • Explain operational issues pertinent to pharmacists such as staff education, MAR documentation and product labeling

Oral Chemotherapy

This 60-minute talk will feature one speaker. The speaker should be actively involved in an oral chemotherapy program. This presentation should focus on meaningful patient outcomes and include actual data from the speaker’s program and experience.

  • Present results of patient outcomes from an oral chemotherapy program (enhanced patient adherence to oral therapy, toxicity management, impact on clinic throughput, etc.)
  • Describe experience determining which methods, metrics, or reports should be utilized to demonstrate quality and safety metrics as well as how data is collected/captured
  • Discuss challenges and tips to successfully being able to report outcomes in an oral chemotherapy clinic

Operational, IT, and Safety Session

This 60-minute session will allow multiple speakers to spend 7 minutes discussing a pearl and have 3 minutes for questions. Submissions should address one of the following objectives:

  • Discuss a pharmacy operational improvement PEARL which resulted in added efficiency for oncology patients and/or workflow
  • Identify an information technology/electronic medical record enhancement PEARL which resulted in improved oncology workflow or patient experience
  • Describe a process improvement PEARL which resulted in improved safety for oncology patients

Please note there will not be a complimentary registration or honorarium for the speakers selected to present for this session.